The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma
In this study, thre patients with unresectable hepatocellular carcinoma were treated with PD-1 inhibitor combined with TACE to achieve good tumor reduction effect and underwent live r cancer resection surgery. For patients with unresectable hepatocellular carcinoma, whether in BCLC stage B or stage C, effective systemic therapy (PD-1 inhibitor) combined with local therapy (TACE) can achieve a high rate of tumor regression and objective response. Some patients may even pursue su rgical treatment opportunities, and the treatment-related adverse reactions are controllable, which is expected to provide new options for extending the survival of unresectable hepatocellular carcinoma patients.
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
More News: Bilirubin | Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Hospitals | Hypothyroidism | Liver Cancer | Pain | Study | Thrombosis